Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation

References

• Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. 2000. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60(24):6921–6926.
   PubMed Web of Science ®Google Scholar
• Basit A, Neradugomma NK, Wolford C, Fan PW, Murray B, Takahashi RH, Khojasteh SC, Smith BJ, Heyward S, Totah RA, et al. 2020. Characterization of differential tissue abundance of major non-CYP enzymes in human. Mol Pharm. 17(11):4114–4124.
   PubMed Web of Science ®Google Scholar
• Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. 2005. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 11(3):1226–1236.
   PubMed Web of Science ®Google Scholar
• Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G. 2009. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol. 27(15):2457–2465.
   PubMed Web of Science ®Google Scholar
• Chen K, Jin M, Zhu Y, Jiang Q, Yu W, Ma X, Yao K. 2006. Genetic polymorphisms of the uridine diphosphate glucuronosyltransferase 1A7 and colorectal cancer risk in relation to cigarette smoking and alcohol drinking in a Chinese population. J Gastroenterol Hepatol. 21(6):1036–1041.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu L, Guo Z, Liang W, He J, Huang L, Deng Q, Tang H, Pan H, Guo M, et al. 2017. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with lung cancer: a meta-analysis. Cancer Chemother Pharmacol. 79(6):1109–1117.
   PubMed Web of Science ®Google Scholar
• Ciotti M, Basu N, Brangi M, Owens IS. 1999. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun. 260(1):199–202. eng.
   PubMed Web of Science ®Google Scholar
• Cui C, Shu C, Cao D, Yang Y, Liu J, Shi S, Shao Z, Wang N, Yang T, Liang H, et al. 2016. UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens. Oncol Lett. 12(5):4231–4237.
   PubMed Web of Science ®Google Scholar
• de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. 2018. Individualization of Irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 57(10):1229–1254.
   PubMed Web of Science ®Google Scholar
• Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. 2002. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol. 62(3):608–617.
   PubMed Web of Science ®Google Scholar
• Haaz MC, Rivory L, Jantet S, Ratanasavanh D, Robert J. 1997. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol. 80(2):91–96.
   PubMedGoogle Scholar
• Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, Sawada J. 2001. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica. 31(10):687–699.
   PubMed Web of Science ®Google Scholar
• Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, et al. 2013. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci. 104(12):1662–1669.
   PubMed Web of Science ®Google Scholar
• Hirose K, Yamashita K, Takada H, Kaneda N, Fukami K, Maruo E, Kitamura M, Hasegawa J, Maeda Y. 2014. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration. Int J Clin Oncol. 19(2):397–402.
   PubMed Web of Science ®Google Scholar
• Hu DG, Marri S, Mackenzie PI, Hulin JA, McKinnon RA, Meech R. 2021. The expression profiles and deregulation of UDP-glycosyltransferase (UGT) genes in human cancers and their association with clinical outcomes. Cancers (Basel). 13(17):4491.
   PubMed Web of Science ®Google Scholar
• Huang CS, Luo GA, Huang ML, Yu SC, Yang SS. 2000. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. Pharmacogenetics. 10(6):539–544.
   PubMedGoogle Scholar
• Huang YH, Galijatovic A, Nguyen N, Geske D, Beaton D, Green J, Green M, Peters WH, Tukey RH. 2002. Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics. 12(4):287–297.
   PubMedGoogle Scholar
• Inoue K, Sonobe M, Kawamura Y, Etoh T, Takagi M, Matsumura T, Kikuyama M, Kimura M, Minami S, Utsuki H, et al. 2013. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. Tohoku J Exp Med. 229(2):107–114.
   PubMed Web of Science ®Google Scholar
• Iwai M, Maruo Y, Ito M, Yamamoto K, Sato H, Takeuchi Y. 2004. Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet. 49(3):123–128.
   PubMed Web of Science ®Google Scholar
• Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, Ratain MJ. 1999. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 65(5):576–582.
   PubMed Web of Science ®Google Scholar
• Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, Aoki Y, Ikushiro S-i, Sakaki T, Yokoi T. 2009. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos. 37(8):1759–1768.
   PubMed Web of Science ®Google Scholar
• Jinno H, Saeki M, Tanaka-Kagawa T, Hanioka N, Saito Y, Ozawa S, Ando M, Shirao K, Minami H, Ohtsu A, et al. 2003. Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10. Drug Metab Dispos. 31(5):528–532.
   PubMed Web of Science ®Google Scholar
• Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, Sawada J. 2003. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos. 31(1):108–113.
   PubMed Web of Science ®Google Scholar
• Maruo Y, Takahashi H, Matsui K, Sato H, Takeuchi Y. 2010. Phase II drug metabolism and individualized drug therapy: a focus on functional genetic variation in UDP-glucuronosyltransferases. CPPM. 8(2):146–166.
   Google Scholar
• Mimura Y, Maruo Y, Ohta Y, Sato H, Takeuchi Y. 2011. Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family. Basic Clin Pharmacol Toxicol. 109(6):486–493.
   PubMed Web of Science ®Google Scholar
• Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y. 2005. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos. 33(5):672–675.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Soda H, Oka M, Kinoshita A, Fukuda M, Fukuda M, Takatani H, Nagashima S, Soejima Y, Kasai T, et al. 2011. Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. J Thorac Oncol. 6(1):121–127.
   PubMed Web of Science ®Google Scholar
• Oguri T, Takahashi T, Miyazaki M, Isobe T, Kohno N, Mackenzie PI, Fujiwara Y. 2004. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res. 24(5A):2893–2896.
   PubMed Web of Science ®Google Scholar
• Sandanaraj E, Jada SR, Shu X, Lim R, Lee SC, Zhou Q, Zhou S, Goh BC, Chowbay B. 2008. Influence of UGT1A9 intronic I399C > T polymorphism on SN-38 glucuronidation in Asian cancer patients. Pharmacogenomics J. 8(3):174–185.
   PubMed Web of Science ®Google Scholar
• Strassburg CP, Manns MP, Tukey RH. 1998. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem. 273(15):8719–8726.
   PubMed Web of Science ®Google Scholar
• Strassburg CP, Vogel A, Kneip S, Tukey RH, Manns MP. 2002. Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut. 50(6):851–856.
   PubMed Web of Science ®Google Scholar
• Sun L, Li M, Zhang L, Teng X, Chen X, Zhou X, Ma Z, Qi L, Wang P. 2017. Differences in UGT1A1 gene mutations and pathological liver changes between Chinese patients with Gilbert syndrome and Crigler-Najjar syndrome type II. Medicine (Baltimore). 96(45):e8620.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y. 2008. Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol. 103(2):131–136.
   PubMed Web of Science ®Google Scholar
• Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T. 1998. Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol. 42(4):280–286.
   PubMed Web of Science ®Google Scholar
• Teh LK, Hashim H, Zakaria ZA, Salleh MZ. 2012. Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia. Indian J Med Res. 136(2):249–259.
   PubMed Web of Science ®Google Scholar
• Teng HC, Huang MJ, Tang KS, Yang SS, Tseng CS, Huang CS. 2007. Combined UGT1A1 and UGT1A7 variant alleles are associated with increased risk of Gilbert's syndrome in Taiwanese adults. Clin Genet. 72(4):321–328.
   PubMed Web of Science ®Google Scholar
• Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, et al. 2006. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res. 66(1):125–133.
   PubMed Web of Science ®Google Scholar
• Tourancheau A, Rouleau M, Guauque-Olarte S, Villeneuve L, Gilbert I, Droit A, Guillemette C. 2018. Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues. Pharmacogenomics J. 18(2):251–261.
   PubMed Web of Science ®Google Scholar
• Troberg J, Jarvinen E, Ge GB, Yang L, Finel M. 2017. UGT1A10 is a high activity and important extrahepatic enzyme: why has its role in intestinal glucuronidation been frequently underestimated? Mol Pharm. 14(9):2875–2883.
   PubMedGoogle Scholar
• Tukey RH, Strassburg CP. 2000. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 40:581–616.
   PubMed Web of Science ®Google Scholar
• Tziotou M, Kalotychou V, Ntokou A, Tzanetea R, Armenis I, Varsou M, Konstantopoulos K, Tsavaris N, Rombos Y. 2014. Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity. Ecancermedicalscience. 8:428.
   PubMedGoogle Scholar
• Valenzuela Jimenez B, Gonzalez Sales M, Escudero Ortiz V, Martinez Navarro E, Perez Ruixo C, Rebollo Liceaga J, Gonzalez Manzano R, Perez Ruixo JJ. 2013. Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokinetics of irinotecan, SN-38 and SN-38G. Farm Hosp. 37(2):111–127.
   PubMedGoogle Scholar
• Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C. 2003. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther. 307(1):117–128.
   PubMed Web of Science ®Google Scholar
• Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, Strassburg CP. 2001. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology. 121(5):1136–1144.
   PubMed Web of Science ®Google Scholar
• Weismuller TJ, Zhou T, Kalthoff S, Lenzen H, Manns MP, Strassburg CP. 2020. Genetic variants of UDP-glucuronosyltransferase 1A genes are associated with disease presentation and outcome in primary sclerosing cholangitis. Liver Int. 40(7):1645–1654.
   PubMed Web of Science ®Google Scholar
• Xiao L, Zhu L, Li W, Li C, Cao Y, Ge G, Sun X. 2018. New insights into SN-38 glucuronidation: evidence for the important role of UDP glucuronosyltransferase 1A9. Basic Clin Pharmacol Toxicol. 122(4):424–428.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wolford C, Basit A, Li AP, Fan PW, Murray BP, Takahashi RH, Khojasteh SC, Smith BJ, Thummel KE, et al. 2020. Regional proteomic quantification of clinically relevant non-cytochrome P450 enzymes along the human small intestine. Drug Metab Dispos. 48(7):528–536.
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu W, Innocenti F, Ratain MJ. 2007. Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. PLoS One. 2(4):e396.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hou J, Feng F, Li D, Jiang Q, Li X, Zhao Q, Li BA. 2017. Genetic polymorphisms in human UDP-glucuronosyltransferases 1A7 and the risk of gastrointestinal carcinomas: a systematic review and network meta-analysis. Oncotarget. 8(39):66371–66381.
   PubMedGoogle Scholar